文献速递中毒与环境急症呼吸衰竭与机械通气重症综合管理与镇静镇痛

新型制剂上市后吡虫啉自服中毒的临床毒性变化

The clinical toxicity of imidacloprid self-poisoning following the introduction of newer formulations.
PubMed 文献 · Clin Toxicol (Phila) · 2020-09-22
一句话结论2007年后新型制剂吡虫啉自服中毒出现死亡(3.0%)和机械通气需求增加(6.0%),毒性较前升高。

该研究在斯里兰卡7家医院前瞻性收集口服吡虫啉自服中毒的临床与人口学数据,对比2002—2007年已发表队列(56例)与2010—2016年新型制剂上市后队列(67例)。两阶段多数患者均表现为恶心、呕吐、上腹痛、头痛等非特异性症状;但2007年前仅1.9%因呼吸衰竭需机械通气且无死亡,2010年后死亡占3.0%、6.0%因呼吸衰竭需机械通气。作者认为毒性变化可能与新制剂所用溶剂有关,也可能与后一队列摄入剂量更高有关,需进一步研究溶剂并持续开展毒物监测。

要点

  • 2010—2016年新型制剂吡虫啉自服中毒队列67例中死亡3.0%,2007年前56例队列无死亡报告。
  • 2010年后6.0%因呼吸衰竭需机械通气,2007年前仅1.9%需机械通气。
  • 两阶段多数患者均为恶心、呕吐、上腹痛、头痛等非特异性症状。
  • 2010年后就诊中位时间2.0小时(IQR 1.5—3.1),2007年前为4小时(IQR 2.3—6.0)。
  • 2010年后摄入中位量27.5 ml(IQR 5.0—71.8),2007年前为15 ml(IQR 10.0—50.0)。

适用人群与场景

  • 斯里兰卡7家医院收治的口服吡虫啉自服中毒患者,数据分别收集于2002—2007年与2010—2016年。

红旗征与不能漏的情况

  • 2010年后队列出现因呼吸衰竭需机械通气(6.0%)及死亡(3.0%),死亡原因分别为一例心肺衰竭、一例长期住院并发大叶性肺炎并在未诊断肝硬化基础上出现失代偿性肝衰竭。

研究设计与关键结果

  • 前瞻性收集7家医院口服吡虫啉自服中毒的临床与人口学数据,对比2002—2007年已发表研究队列(56例)与2010—2016年新型制剂上市后队列(67例)。
  • 2007年前就诊中位时间4小时(IQR 2.3—6.0),2010年后2.0小时(IQR 1.5—3.1);摄入中位量2007年前15 ml(IQR 10.0—50.0),2010年后27.5 ml(IQR 5.0—71.8)。
  • 2007年前仅1.9%因呼吸衰竭需机械通气、无死亡报告;2010年后死亡占3.0%、6.0%因呼吸衰竭需机械通气。

证据类型、等级与局限

  • 研究类型:前瞻性临床与人口学数据收集,对比两个时期队列(2002—2007年已发表队列与2010—2016年新制剂上市后队列)。
  • 原文结论指出毒性变化可能与新制剂所用溶剂有关,也可能与后一队列摄入吡虫啉剂量更高有关。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,尽管急性吡虫啉暴露通常与轻度非特异性症状相关,但新型制剂上市后毒性特征已发生变化,出现死亡病例及需机械通气病例增加。
  • 作者认为,需进一步研究新型制剂中的溶剂,并持续开展毒物监测。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Self-poisoning with imidacloprid has been previously shown to have low toxicity in humans. Since 2007 newer formulations of Imidacloprid with unknown solvents have been introduced and the potential clinical consequences of these products have not been described.

METHODS: Clinical and demographic data were prospectively collected from admissions following oral ingestion of imidacloprid from seven hospitals in Sri Lanka. Data was collected from 2002 to 2007 in an already published study. We compared this data on poisonings collected from 2010 to 2016 following the introduction of new formulations of imidacloprid.

RESULTS: From 2002-2007, there were 56 patients with ingestion to imidacloprid compared to 67 patients post 2010 The median time to presentation prior to 2007 was 4 h (IQR 2.3-6.0 hrs) and post 2010 was only 2.0 hr (IQR 1.5 to 3.1 hrs). The median amount ingested was 15 ml (IQR 10.0-50.0mls) prior to 2007 and 27.5mls (IQR 5.0-71.8mls) post 2010. In both studies most patients developed non-specific symptoms including nausea, vomiting, epigastric pain and headache. However, prior to 2007 only 1.9% of the cohort required mechanical ventilation due to respiratory failure and there were no reported deaths. In contrast, post 2010; deaths occurred in 3.0% of the cohort and 6.0% required mechanical ventilation for respiratory failure. The cause of mortality was due to one case of cardiorespiratory failure and the other due to a prolonged admission complicated with lobar pneumonia leading to decompensated liver failure on the background of undiagnosed liver cirrhosis.

CONCLUSION: Although acute exposure to imidacloprid is usually associated with mild non-specific symptoms, since the introduction of new formulations of imidacloprid, the toxic profile has changed with reported cases of death as well as an increase in cases requiring mechanical ventilation. The change in toxicity could be due to the solvents used in the newer formulations but also due to higher dose of imidacloprid described in our latter cohort. Further research into these solvents needs to be done and continued toxicovigilance is required.

来源:Clin Toxicol (Phila),查看原文。版权归原作者所有。

参考来源

  1. Perananthan V, Mohamed F, Shahmy S, et al. The clinical toxicity of imidacloprid self-poisoning following the introduction of newer formulations. Clin Toxicol (Phila). 2020. PMID: 32959700. doi:10.1080/15563650.2020.1815760

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。